**Chapter 6**

*Type 2 Diabetes - From Pathophysiology to Modern Management*

adjunctive to insulin therapy in type 1 diabetes: The EASE trials. Diabetes

[117] Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA adverse event reporting system. The Lancet Diabetes & Endocrinology.

[118] Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. The Journal of Clinical Endocrinology.

[119] Wanner C, Toto RD, Gerich J, Hach T, Salsali A, Kim G. No increase in bone fractures with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). Journal of the American Society of Nephrology.

Care. 2018;**41**(12):2560-2569

2017;**5**(9):680-681

2016;**101**(1):44-51

2013;**24**(Suppl):S205A

and tolerability of canagliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase 3 study results. Postgraduate Medicine.

[110] Kim G, Gerich J, Salsali A, Hach T, Hantel S, Woerle HJ, et al. Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. Diabetologie und Stoffwechsel.

[111] Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and metaanalysis. Annals of Internal Medicine.

[112] Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. Journal of Diabetes and its Complications. 2013;**27**(5):473-478

[113] Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. Journal of Diabetes

Investigation. 2016;**7**(2):135-138

[114] Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes

[115] Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and

[116] Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as

Care. 2015:dc151251

diabetic ketoacidosis.

2014;**126**(3):16-34

2014;**9**(S 01):P140

2013;**159**(4):262-274

**98**
